FDA Analyzing Non-Inspected Foreign Firms Which Are Named in NDAs
Executive Summary
FDA's next step in analyzing data from the Operational and Administrative System for Import Support will be to identify non-inspected foreign drug firms referenced in approved human or animal drug applications.
You may also be interested in...
Rx Import Bill Undercuts FDA Approach To Quality Control, Lilly Exec Testifies
FDA's process focus in GMP regulation illustrates the importance of manufacturer control over importation into the U.S., Lilly Europe/North America Area Quality Control Leader Nikki Mehringer told the House Commerce/Oversight Subcommittee Oct. 3.
Rx Import Bill Undercuts FDA Approach To Quality Control, Lilly Exec Testifies
FDA's process focus in GMP regulation illustrates the importance of manufacturer control over importation into the U.S., Lilly Europe/North America Area Quality Control Leader Nikki Mehringer told the House Commerce/Oversight Subcommittee Oct. 3.
Bulk Drug Import Quality Reports May Be Required From U.S. Firms
Pharmaceutical manufacturers may be required to notify FDA when they receive bulk drugs of poor quality, FDA Associate Commissioner for Regulatory Affairs Dennis Baker told a House subcommittee hearing June 8.